10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing

2. Bristol-Myers Squibb Company (NYSE:BMY)

Forward P/E as of June 19: 7.74

Analysts’ Price Target Upside as of June 19: 27.09%

Number of Hedge Fund Holdings as of Q1 2025: 69

Bristol-Myers Squibb Company (NYSE:BMY) is the third biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 17, the company announced a quarterly cash dividend of $0.60 per share on its common stock. This is the 95th consecutive year that the conglomerate has paid a dividend.

The latest dividend is payable on August 1, 2025, a slight decline (by $0.02) compared to the previous payment in February this year. However, the payment is higher than the $0.57 per share for all four payments in 2023. In 2024, the company started the payment with a $0.60 per share dividend (5.26% higher than 2023) on February 1, which was maintained for all four payments of the year.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical firm. It discovers, develops, and markets prescription medicines for serious diseases in areas like oncology, hematology, immunology, cardiovascular, and neuroscience. Its leading products include Opdivo, Eliquis, Revlimid, Yervoy, and Sotyktu.